论文部分内容阅读
近年来,乳腺癌的治疗方法逐渐增多,所以我们需要乳腺癌的预后评估系统对患者进行预后危险度分级,从而为患者选择最合适的治疗方法。目前乳腺癌预后评估系统有两类:一类是经典的基于临床病理学特征的预后评估系统:Nottingham预后指数、St.Gallen国际乳腺癌危险评估系统和Adjuvant计算机评估系统;另一类是基于基因表达谱的预后评估系统:21-基因复发评分、70-基因芯片。本文就乳腺癌预后评估系统的种类、应用现状、未来展望作一综述。
In recent years, there has been an increase in the treatment of breast cancer, so we need a prognostic assessment system for breast cancer to classify the patient’s risk of prognosis so as to select the most appropriate treatment for the patient. Currently there are two types of breast cancer prognostic assessment system: one is the classic prognostic assessment system based on clinicopathological features: the Nottingham Prognosis Index, the St. Gallen International Breast Cancer Risk Assessment System and the Adjuvant Computer Assessment System; the other is based on the gene Prognostic Assessment of Expression Profiles System: 21-Gene Recurrence Score, 70-Gene Chip. This article reviews the types of breast cancer prognosis assessment system, application status, future prospects for a review.